Alexion data at 9th Joint ECTRIMS-ACTRIMS Meeting (MSMilan2023) showcase impact of C5 inhibition in neuromyelitis optica spectrum disorder
Alexion, AstraZeneca Rare Disease, will present new data at MSMilan2023, the 9th Joint Meeting of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-ACTRIMS), taking place 11 to 13 October 2023.
Real-world and clinical data will provide further evidence to support the established safety and efficacy of Ultomiris (ravulizumab) and Soliris (eculizumab) in treating anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD), furthering the Company’s ambition to redefine care for people living with this disease.
Reinforcing the potential of C5 inhibition to transform treatment landscape for AQP4 Ab+ NMOSD: A late-breaking poster presentation will detail encouraging safety findings for patients with AQP4 Ab+ NMOSD who switched from rituximab to C5 inhibitor therapy in the Phase III CHAMPION-NMOSD and PREVENT clinical trials. This post-hoc analysis will show no differences in safety outcomes among patients who used rituximab three to twelve months prior to their first dose of Ultomiris or Soliris and provide information to guide clinical decision-making when considering a switch from rituximab to C5 inhibitor therapy.
Additionally, three-year post-marketing surveillance data of Soliris among Japanese patients has been shortlisted to be qualified for one of the Five Best Poster Awards at the Congress. Findings will illustrate that the real-world safety and efficacy of Soliris in Japanese patients with AQP4 Ab+ NMOSD are consistent with results from the Phase III PREVENT trial. The results will also show that concomitant immunosuppressive therapy (IST) use decreased over time among patients treated with Soliris, reinforcing the potential of Soliris to reduce IST burden for patients. Further, a poster presentation will outline long-term safety data in Ultomiris- and Soliris-treated patients from clinical trials and post-marketing surveillance across indications, with a focus on meningococcal infection data. Results will show meningococcal infection rates and infection-related mortality rates remained stable, even as the number of patients treated with Soliris increased over time. In addition, results will indicate comparable rates among Ultomiris-treated patients.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins